Novartis exercises its option to license Ionis’ RNA-targeting cardiovascular drug, adding to its cardiovascular treatment portfolio, as Entresto reaches the three-year mark on its patent.
Alnylam received US FDA approval for its first-in-class RNAi treatment, Onpattro, but a spokesperson confirmed manufacturing for the treatment is a complicated affair.